All the Active Ingredient Drugs
Quinolone. Ciprofloxacin (as HCl) 3 mg/ml. EYE AND EAR DROPS (SOL.): 5 ml.
Adults and child from 1 yr:
Corneal ulc.: 2 drops every 15 mins. for
first 6 hrs., then 2 drops every 30 mins.
for rest of day. 2nd day: 2 drops hrly.
On 3rd-14th day: 2 drops every 4 hrs.
for up to 14 days.
Bact. conjunct: 1-2 drops into conjuct.
sac(s) every 2 hrs. for 2 days, then 1-2
drops every 4 hrs. for next 5 days.
Otic use: 3 to 4 drops, 2-4 /d, or more
frequently, if required.
In gen., the duration of tmt does not
exceed 5-10 ds.
For either ind. a max. duration of ther.
of 21 days is recommend.
Corneal ulc., conjunct. caused by suscep.
gram pos., gram neg. microorg. for adults
and ped. pts > 1 yr.
For local./diff. otitis externa accomp. by a
strong inflamm. react. and of which the
strains are suscept., and for the acute flare-up of a chronic otitis media. In this
case, a mucopurulent secret.
In other infect. of the ear in which
Pseudom. aerug. and/or other suscept.
strains may be suspect., it can be used
under the strict superv. of an ear specialist.
It must be understood that this is not a
routine tmt and improper use must be
avoided.
C/I: Hypersens. to the product or other
quinolones.
Fluoroquinolones, Quinolone. Ciprofloxacin (as lactate) 2 mg/ml. BOTTLE: 10, 24 × 100 ml, 200 ml. Dosage ajust. accord. to the type of infec.
Adults: Broad spectrum antibiotic for infec. caused by ciprofloxacin sensit. pathogens.
Child. & adolesc.: Broncho-pulmon., infec. in cystic fibrosis (CF) caused by Pseudomonas a.
Complic. UTS’s and pyelonephritis.
Inhalation anthrax (post-exposure prophylax. & curative tmt.).
Ciprofloxacin may also be used to treat severe infec. in child. & adolesc. when there is no other alternative.
Tmt. should be init. only by physicians who are experienced in the tmt. of CF and/or severe infec. in child. & adolesc.
C/I: Hypersens. to the active ingredient/ other quinolones. Concom. admin. of ciprofloxacin and tizanidine.
Fluoroquinolone. Ciprofloxacin (as hydrochloride) 500 mg. CAPS: 10 x 500mg. Upper & lower respirat. tract infec.: 500-750mg ×2/d for 7-14 d.
Malig. extern. otitis: 750 mg ×2/d for 28 d. up to 3 mnths.
Uncomplic. cystitis: 250-500mg ×2/d for 3 d. (in pre-menopaus. women, 500 mg single dose may be used).
Complic. cystitis, Uncomplic. pyelonephritis: 500 mg ×2/d for 7 d.
Complic. pyelonephritis: 500-750 mg ×2/d for at least 10 d.
Prostatitis: 500-750 mg ×2/d for at least 14 d.
Gonococcal urethritis & cervicitis: 500mg as a single dose.
Epididymo-orchitis & pelvic inflamm. dis.: 500-750mg ×2/d for at least 14 d.
Diarrhoea caused by bact. pathogens includ. Shigella spp. other than Shigella dysenteriae type 1 and empirical tmt. of severe travellers' diarrhea: 500mg twice dly. for 1 d.
Diarrhoea caused by Shigella dysenteriae type 1: 500mg ×2/d for 5 d.
Diarrhoea caused by Vibrio cholera:
500mg ×2/d for 3 d.
Typhoid fever: 500mg ×2/d for 7 d.
Intra-abdom. infec. due to Gram-neg. bact.: 500-750mg ×2/d for 5-14 d.
Infec. of the skin & soft tissue: 500-750mg ×2/d for 7-14 d.
Bone & joint infec.: 500-750mg ×2/d for max. of 3 mnths.
Neutropenic pts. with fever suspected to be due to a bact. infec.
Ciprofloxacin should be co-admin. with appropriate antibact. agent(s) in accord. to official guidance: 500-750mg ×2/d over the entire period of neutrop.
Prophylaxis of invas. infec. due to Neisseria meningitidis: 500 mg as a single dose.
Inhalat. anthrax post-exposure prophylax., curative tmt. for persons able to receive tmt. by oral route when clinic. appropriate. Drug admin. should begin as soon as possible after susp. or confir. exposure: 500mg ×2/d for 60 d. from the confirm.of Bacillus anthracis exposure.
See lit.
Ped.population: CF: 20 mg/kg bdy. wt. ×2/d with a max. of 750 mg per dose for 10-14 days.
Complic. UTI's & pyelonephritis: 10 mg/kg bdy. wt. ×2/d to 20 mg/kg bdy. wt. ×2/d with a max. of 750 mg/dose for 10-21 d. Inhal. anthrax post-exposure prophylax. & curative tmt. for persons able to receive tmt. by oral route when clinic. appropriate. Drug admin. should begin as soon as possible after susp. or confirm. exposure: 10 mg/kg bdy. wt.×2/d to 15 mg/kg bdy. wt.×2/d with a max. of 500 mg per dose for 60 d. from the confirm. of Bacillus anthracis exposure.
Other severe infec.: 20 mg/kg bdy. wt. ×2/d with a max. of 750 mg/dose (durat. of tmt. accord. to the type of infec.). See lit.
Adult.: Broad spect. antibiot. for infec. caused by ciprofloxacin sensit. pathogens.
Child.& adolesc.: Broncho -pulmon. infec. in CF caused by Pseudomonas aeruginosa.
Complic. UTI's &pyelonephritis.
Inhal. anthrax (post-exposure prophylax. & curative tmt.).
Ciprofloxacin may also be used to treat severe infec. in child. & adolesc. when there is no other alternative.
Tmt. should be initiated only by physicians who are experienc. in the tmt. of CF and/or severe infec. in child. & adolesc. See lit.
C/I: Hypersens. to the active subst., to other quinolones. Concom. admin. with tizanidine. See lit.
